Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 4:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 2,462 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Ovarian Tumors Clear all
Completed Phase 1 Interventional

A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors

NCT03872947
View directory record Official record
Conditions
Solid Tumor, Colorectal Cancer, Cholangiocarcinoma, Bladder Cancer, Ovarian Cancer, Gastric Cancer, Palpable Subcutaneous Malignant Lesions, Renal Cell Carcinoma, Melanoma, Epithelial Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
Interventions
TRK-950, Irinotecan, Leucovorin, 5-FU, Gemcitabine, Cisplatin, Carboplatin, Ramucirumab, Paclitaxel, Nivolumab, Pembrolizumab, Imiquimod Cream, Bevacizumab, PLD
Biological · Drug
Lead sponsor
Toray Industries, Inc
Industry
Eligibility
18 Years and older
Enrollment
138 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
13
States / cities
Scottsdale, Arizona • Tucson, Arizona • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Oct 8, 2026 · Synced Oct 20, 2026, 4:57 AM EDT
Terminated Phase 1 Interventional

Monoclonal Antibody Therapy in Treating Patients With Ovarian Epithelial Cancer, Melanoma, Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Non-Small Cell Lung Cancer

NCT00039091
View directory record Official record
Conditions
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Recurrent Melanoma, Recurrent Non-small Cell Lung Cancer, Recurrent Ovarian Epithelial Cancer, Stage IV Melanoma, Stage IV Non-small Cell Lung Cancer
Interventions
ipilimumab
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
19 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 5, 2018 · Synced Oct 20, 2026, 4:57 AM EDT
Not listed Phase 1 Interventional

Dose Escalation of RMC-4630 Monotherapy in Relapsed/Refractory Solid Tumors

NCT03634982
View directory record Official record
Conditions
Solid Tumors
Interventions
RMC-4630
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
133 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
12
States / cities
Scottsdale, Arizona • Duarte, California • Orange, California + 9 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2022 · Synced Oct 20, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Bevacizumab With or Without Everolimus in Treating Patients With Recurrent or Persistent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

NCT00886691
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Bevacizumab, Everolimus, Laboratory Biomarker Analysis, Placebo
Biological · Drug · Other
Lead sponsor
GOG Foundation
Network
Eligibility
18 Years and older · Female only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
45
States / cities
Phoenix, Arizona • Burbank, California • Los Angeles, California + 32 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2022 · Synced Oct 20, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

A Trial of Intravenous Denileukin Diftitox in Stage III or IV Ovarian Cancer

NCT00880360
View directory record Official record
Conditions
Epithelial Ovarian Cancer, Extraovarian Peritoneal Cancer, Fallopian Tube Carcinoma
Interventions
Ontak
Drug
Lead sponsor
The University of Texas Health Science Center at San Antonio
Other
Eligibility
18 Years and older · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated Mar 27, 2018 · Synced Oct 20, 2026, 4:57 AM EDT
Active, not recruiting Phase 2 Interventional

Pembrolizumab in Treating Participants With Recurrent Ovarian Cancer

NCT03732950
View directory record Official record
Conditions
Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma
Interventions
Pembrolizumab
Biological
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
Los Angeles, California • Minneapolis, Minnesota • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2024 · Synced Oct 20, 2026, 4:57 AM EDT
Withdrawn Phase 1Phase 2 Interventional

DCVax-L Vaccination With CD3/CD28 Costimulated Autologous T-Cells for Recurrent Ovarian or Primary Peritoneal Cancer

NCT00603460
View directory record Official record
Conditions
Ovarian Cancer, Primary Peritoneal Cancer
Interventions
DCVax-L and T Cells
Biological
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older · Female only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 2, 2017 · Synced Oct 20, 2026, 4:57 AM EDT
Terminated Phase 1 Interventional

A Study of PF-07820435 as a Single Agent and in Combination in Participants With Advanced Solid Tumors

NCT06285097
View directory record Official record
Conditions
Neoplasms, Non-small-cell Lung Cancer, Melanoma, Squamous Cell Carcinoma of the Head and Neck, Renal Cell Carcinoma, Urothelial Carcinoma, Colorectal Carcinoma, Ovarian Carcinoma
Interventions
PF-07820435, Sasanlimab
Drug · Biological
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
9 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
6
States / cities
Sarasota, Florida • Grand Rapids, Michigan • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 17, 2025 · Synced Oct 20, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Carevive Survivor Care Planning System in Improving Quality of Life in Breast Cancer Survivors

NCT03198286
View directory record Official record
Conditions
Stage I Breast Cancer, Stage I Cervical Cancer, Stage I Ovarian Cancer, Stage I Uterine Corpus Cancer, Stage IA Breast Cancer, Stage IA Cervical Cancer, Stage IA Ovarian Cancer, Stage IA Uterine Corpus Cancer, Stage IB Breast Cancer, Stage IB Cervical Cancer, Stage IB Ovarian Cancer, Stage IB Uterine Corpus Cancer, Stage IC Ovarian Cancer, Stage II Breast Cancer, Stage II Cervical Cancer, Stage II Ovarian Cancer, Stage II Uterine Corpus Cancer, Stage IIA Breast Cancer, Stage IIA Cervical Cancer, Stage IIA Ovarian Cancer, Stage IIB Breast Cancer, Stage IIB Cervical Cancer, Stage IIB Ovarian Cancer, Stage IIC Ovarian Cancer, Stage III Breast Cancer, Stage III Cervical Cancer, Stage III Ovarian Cancer, Stage III Uterine Corpus Cancer, Stage IIIA Breast Cancer, Stage IIIA Cervical Cancer, Stage IIIA Ovarian Cancer, Stage IIIA Uterine Corpus Cancer, Stage IIIB Breast Cancer, Stage IIIB Cervical Cancer, Stage IIIB Ovarian Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC Breast Cancer, Stage IIIC Ovarian Cancer, Stage IIIC Uterine Corpus Cancer
Interventions
Informational Intervention
Other
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older · Female only
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
2
States / cities
Philadelphia, Pennsylvania • Reading, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Oct 20, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Nirogacestat in Ovarian Granulosa Cell Tumors

NCT05348356
View directory record Official record
Conditions
Ovarian Granulosa-Stromal Tumor, Ovarian Granulosa Cell Tumor, Ovarian Cancer
Interventions
Nirogacestat
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years and older · Female only
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
16
States / cities
Los Angeles, California • Orlando, Florida • Tampa, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Oct 20, 2026, 4:57 AM EDT
Terminated Phase 2Phase 3 Interventional

Oral Administration of DCI to Women With PCOS

NCT00497653
View directory record Official record
Conditions
Polycystic Ovary Syndrome
Interventions
DCI, Placebo
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years to 40 Years · Female only
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2009
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 16, 2011 · Synced Oct 20, 2026, 4:57 AM EDT
Terminated Phase 3 Interventional Results available

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

NCT05092360
View directory record Official record
Conditions
Platinum-resistant Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Interventions
Nemvaleukin and Pembrolizumab Combination, Pembrolizumab, Nemvaleukin, Pegylated Liposomal Doxorubicin (PLD), Paclitaxel, Topotecan, Gemcitabine
Biological · Drug
Lead sponsor
Mural Oncology, Inc
Industry
Eligibility
18 Years and older · Female only
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2025
U.S. locations
37
States / cities
Birmingham, Alabama • Anchorage, Alaska • Tucson, Arizona + 31 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Oct 20, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

TUBectomy With Delayed Oophorectomy in High Risk Women to Assess the Safety of Prevention

NCT04294927
View directory record Official record
Conditions
BRCA1 Gene Mutation, BRCA2 Gene Mutation, RAD51C Gene Mutation, RAD51D Gene Mutation, BRIP1 Gene Mutation, Ovarian Cancer
Interventions
Risk-reducing salpingectomy with delayed oophorectomy, Risk-reducing salpingo-oophorectomy
Procedure
Lead sponsor
University Medical Center Nijmegen
Other
Eligibility
25 Years to 50 Years · Female only
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
11
States / cities
Chicago, Illinois • Boston, Massachusetts • Rochester, Minnesota + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 6, 2026 · Synced Oct 20, 2026, 4:57 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Triple Negative Breast Cancer and Germline Hereditary Breast and Ovarian Cancer Mutation Carrier Registry

NCT02302742
View directory record Official record
Conditions
Breast Cancer, Hereditary Breast and Ovarian Cancer
Interventions
Not listed
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
Not listed
Enrollment
3,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2026
U.S. locations
11
States / cities
Hays, Kansas • Kansas City, Kansas • Overland Park, Kansas + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 20, 2026, 4:57 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

In Vitro Maturation (IVM) of Human Oocytes

NCT01843569
View directory record Official record
Conditions
Polycystic Ovarian Syndrome (PCOS), Patients Sensitive to Exogenous Gonadotropins, Ovarian Hyper Stimulation Syndrome (OHSS)
Interventions
In Vitro maturation
Biological
Lead sponsor
Northwell Health
Other
Eligibility
25 Years to 42 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
1
States / cities
Manhasset, New York
Source: ClinicalTrials.gov public record
Updated Nov 16, 2020 · Synced Oct 20, 2026, 4:57 AM EDT
Not listed Not applicable Interventional

Family History Study on Cancer Risk

NCT04145388
View directory record Official record
Conditions
Lynch Syndrome, Colorectal Cancer, Breast Cancer, Ovarian Cancer, Family Characteristics, Genetic Predisposition
Interventions
online cancer risk assessment, Usual care
Other
Lead sponsor
Kaiser Permanente
Other
Eligibility
25 Years to 75 Years
Enrollment
18,623 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Oakland, California
Source: ClinicalTrials.gov public record
Updated Feb 14, 2024 · Synced Oct 20, 2026, 4:57 AM EDT
Completed Phase 1 Interventional

Safety and Pharmacokinetics of DMUC5754A Administered Intravenously to Patients With Platinum-Resistant Ovarian Cancer or Unresectable Pancreatic Cancer

NCT01335958
View directory record Official record
Conditions
Ovarian Cancer, Pancreatic Cancer
Interventions
DMUC5754A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
4
States / cities
Boston, Massachusetts • Oklahoma City, Oklahoma • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 20, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Everolimus and Letrozole in Treating Patients With Recurrent Hormone Receptor Positive Ovarian, Fallopian Tube, or Primary Peritoneal Cavity Cancer

NCT02283658
View directory record Official record
Conditions
Ovarian Endometrioid Adenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Serous Surface Papillary Adenocarcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Ovarian Germ Cell Tumor, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Ovarian Carcinoma
Interventions
Everolimus, Laboratory Biomarker Analysis, Letrozole
Drug · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
2
States / cities
Jacksonville, Florida • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 20, 2026, 4:57 AM EDT
Completed Not applicable Interventional

Nonmyeloablative Allogeneic Transplant

NCT01272817
View directory record Official record
Conditions
Aplastic Anemia, Paroxysmal Nocturnal Hemoglobinuria, Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Hodgkin's Lymphoma, Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma, Multiple Myeloma, Waldenstrom Macroglobulinemia, Breast Cancer, Renal Cell Carcinoma, Melanoma, Sarcoma, Ovarian Cancer, Thymoma
Interventions
Nonmyeloablative Allogeneic Transplant
Procedure
Lead sponsor
Scripps Health
Other
Eligibility
18 Years to 72 Years
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Nov 23, 2022 · Synced Oct 20, 2026, 4:57 AM EDT
Terminated Phase 2 Interventional Results available

Pembrolizumab in Subjects With Incurable Platinum-Refractory Germ Cell Tumors

NCT02499952
View directory record Official record
Conditions
Germ Cell Neoplasms, Testicular Neoplasms, Non Seminomatous Germ Cell Tumors, Mediastinal Neoplasms, Genital Neoplasms, Male, Genital Neoplasms, Female, Ovarian Neoplasms
Interventions
Pembrolizumab
Drug
Lead sponsor
Nasser Hanna, M.D.
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
2
States / cities
Indianapolis, Indiana • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Oct 20, 2026, 4:57 AM EDT
Recruiting Phase 2Phase 3 Interventional

A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT06161025
View directory record Official record
Conditions
Solid Cancer
Interventions
R-DXd, Paclitaxel, Topotecan, PLD
Drug
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
43
States / cities
Anchorage, Alaska • New Haven, Connecticut • Coral Gables, Florida + 32 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 20, 2026, 4:57 AM EDT
Recruiting Not applicable Interventional

Distance-Based Exercise to Preserve Function and Prevent Disability

NCT07059884
View directory record Official record
Conditions
Localized Malignant Solid Neoplasm, Anal Cancer, Bladder (Urothelial, Transitional Cell) Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Endometrial Cancer, Esophageal Cancer, Gall Bladder Cancer, Gastric Cancer, Kidney Cancer, Liver Cancer, Lung Cancer, Head and Neck Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Rectal Cancer, Sarcoma
Interventions
Exercise Intervention, Telemedicine, Aerobic Exercise Intervention, Accelerometry, Questionnaire Administration, Interview, Electronic Health Record Review
Other · Procedure
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
23
States / cities
Dublin, California • Fremont, California • Fresno, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 20, 2026, 4:57 AM EDT
Terminated Early Phase 1 Interventional

Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer

NCT00499733
View directory record Official record
Conditions
Cancer
Interventions
cyclophosphamide, Cryoablation
Drug · Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 120 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 18, 2019 · Synced Oct 20, 2026, 4:57 AM EDT
Completed Phase 2 Interventional Results available

Study of Immune Response Modifier in the Treatment of Breast, Ovarian, Endometrial and Cervical Cancers

NCT00319748
View directory record Official record
Conditions
Breast Cancer, Ovarian Cancer, Endometrial Cancer, Cervical Cancer
Interventions
852A
Drug
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 20, 2026, 4:57 AM EDT